These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 32407486)

  • 41. Potent antifungal activity of extracts and pure compound isolated from pomegranate peels and synergism with fluconazole against Candida albicans.
    Endo EH; Cortez DA; Ueda-Nakamura T; Nakamura CV; Dias Filho BP
    Res Microbiol; 2010 Sep; 161(7):534-40. PubMed ID: 20541606
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro synergism of fluconazole and baicalein against clinical isolates of Candida albicans resistant to fluconazole.
    Huang S; Cao YY; Dai BD; Sun XR; Zhu ZY; Cao YB; Wang Y; Gao PH; Jiang YY
    Biol Pharm Bull; 2008 Dec; 31(12):2234-6. PubMed ID: 19043205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanisms of action of antimicrobial peptides ToAP2 and NDBP-5.7 against Candida albicans planktonic and biofilm cells.
    do Nascimento Dias J; de Souza Silva C; de Araújo AR; Souza JMT; de Holanda Veloso Júnior PH; Cabral WF; da Glória da Silva M; Eaton P; de Souza de Almeida Leite JR; Nicola AM; Albuquerque P; Silva-Pereira I
    Sci Rep; 2020 Jun; 10(1):10327. PubMed ID: 32587287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ascorbic acid decreases the antifungal effect of fluconazole in the treatment of candidiasis.
    Wang Y; Jia XM; Jia JH; Li MB; Cao YY; Gao PH; Liao WQ; Cao YB; Jiang YY
    Clin Exp Pharmacol Physiol; 2009 Oct; 36(10):e40-6. PubMed ID: 19413603
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium.
    Moosa MY; Sobel JD; Elhalis H; Du W; Akins RA
    Antimicrob Agents Chemother; 2004 Jan; 48(1):161-7. PubMed ID: 14693534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of biofilm- and hyphal- development, two virulent features of Candida albicans by secondary metabolites of an endophytic fungus Alternaria tenuissima having broad spectrum antifungal potential.
    Chatterjee S; Ghosh R; Mandal NC
    Microbiol Res; 2020 Feb; 232():126386. PubMed ID: 31816593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans.
    Jin J; Guo N; Zhang J; Ding Y; Tang X; Liang J; Li L; Deng X; Yu L
    Lett Appl Microbiol; 2010 Sep; 51(3):351-7. PubMed ID: 20681969
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Strong antifungal activity of SS750, a new triazole derivative, is based on its selective binding affinity to cytochrome P450 of fungi.
    Matsumoto M; Ishida K; Konagai A; Maebashi K; Asaoka T
    Antimicrob Agents Chemother; 2002 Feb; 46(2):308-14. PubMed ID: 11796335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clearance of a fluconazole-resistant Candida albicans strain after switching antifungal therapy and initiation of triple therapy for HIV infection.
    Ruhnke M; Adler A; Müller FM
    Clin Microbiol Infect; 2000 Apr; 6(4):220-3. PubMed ID: 11168112
    [No Abstract]   [Full Text] [Related]  

  • 50. Is there any relationship between fluconazole resistance and some virulence factors in Candida albicans strains?
    Ozkütük A; Ergon C; Ozdemir S; Yulug N
    J Chemother; 2003 Dec; 15(6):616-7. PubMed ID: 14998091
    [No Abstract]   [Full Text] [Related]  

  • 51. In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso).
    Zida A; Yacouba A; Bamba S; Sangare I; Sawadogo M; Guiguemde T; Kone S; Traore LK; Ouedraogo-Traore R; Guiguemde RT
    J Mycol Med; 2017 Dec; 27(4):469-475. PubMed ID: 28754462
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans.
    Petraitis V; Petraitiene R; Kelaher AM; Sarafandi AA; Sein T; Mickiene D; Bacher J; Groll AH; Walsh TJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3959-67. PubMed ID: 15388459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
    De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
    J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro antifungal activity of cassia fistula extracts against fluconazole resistant strains of Candida species from HIV patients.
    Sony P; Kalyani M; Jeyakumari D; Kannan I; Sukumar RG
    J Mycol Med; 2018 Mar; 28(1):193-200. PubMed ID: 28838629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of T-2307, a novel arylamidine, against ocular complications of disseminated candidiasis in mice.
    Abe M; Nakamura S; Kinjo Y; Masuyama Y; Mitsuyama J; Kaku M; Miyazaki Y
    J Antimicrob Chemother; 2019 May; 74(5):1327-1332. PubMed ID: 30753506
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploring the thiazole scaffold for the identification of new agents for the treatment of fluconazole resistant Candida.
    Meleddu R; Distinto S; Corona A; Maccioni E; Arridu A; Melis C; Bianco G; Matyus P; Cottiglia F; Sanna A; De Logu A
    J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1672-7. PubMed ID: 26745285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-activity relationship studies of ultra-short peptides with potent activities against fluconazole-resistant Candida albicans.
    Ng SMS; Yap JM; Lau QY; Ng FM; Ong EHQ; Barkham T; Teo JWP; Alfatah M; Kong KW; Hoon S; Arumugam P; Hill J; Brian Chia CS
    Eur J Med Chem; 2018 Apr; 150():479-490. PubMed ID: 29549835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drosophila melanogaster as a Rapid and Reliable In Vivo Infection Model to Study the Emerging Yeast Pathogen Candida auris.
    Wurster S; Albert ND; Kontoyiannis DP
    Methods Mol Biol; 2022; 2517():299-316. PubMed ID: 35674964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis, antifungal activity of caffeic acid derivative esters, and their synergism with fluconazole and nystatin against Candida spp.
    Sardi JC; Gullo FP; Freires IA; Pitangui NS; Segalla MP; Fusco-Almeida AM; Rosalen PL; Regasini LO; Mendes-Giannini MJ
    Diagn Microbiol Infect Dis; 2016 Dec; 86(4):387-391. PubMed ID: 27638348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant
    Locke JB; Almaguer AL; Donatelli JL; Bartizal KF
    Infect Dis Obstet Gynecol; 2018; 2018():7040498. PubMed ID: 29681727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.